Adrenomedullin (AM) and their receptor components, CRLR, RAMP1, RAMP2 and RAMP3 are widely expressed in the central nervous system, including cerebellum. Recent evidence suggests a role for cerebellar adrenomedullinergic system in blood pressure (BP) regulation. We assessed AM, RAMP1, RAMP2, RAMP3 and CRLR expression; and AM receptor signaling pathway in the cerebellar vermis of WKY and SHR rats. Our findings demonstrated that CRLR, RAMP1 and RAMP3 expression was higher in cerebellum of SHR rats, while AM and RAMP2 expression was lower than those of WKY rats, both in 8 and 16 week old rats. In regard of AM signaling pathways, we show that AM activates ERK, increases cAMP and cGMP production and NO accumulation. These effects are mediated through the activation of AM 1 receptor, since AM 22-52 blunted AM action, meanwhile AM increase of cAMP production is also mediated through stimulation of AM2 and CGRP receptors. Furthermore, AM decreased TBARS production and antioxidant enzymes basal activity: catalase (CAT), glutathione peroxidase (GPx) and superoxide dismutase (SOD). During hypertension, AM signaling pathways in the cerebellar vermis are altered. Effectively, in WKY rats AM decreased the activity of three antioxidant enzymes and TBARS production, while in SHR rats AM was unable to affect these signaling pathways; AM-induced ERK1/2 activation in cerebellum of the SHR was smaller in magnitude than in WKY; and AM increased cGMP/NO production in cerebellar vermis of the WKY rats, while in SHR rats AM was unable to stimulate this signaling pathway. We anticipated a possible functional role of cerebellar AM on BP regulation. Indeed, in vivo microinjection of AM into the cerebellar vermis caused a profound, dose dependent, hypotensive effect in SHR but not in normotensive WKY rats. Co-injections of a putative AM receptor antagonist, AM 22-52 abolished the decreases in MAP evoked by AM, showing that AM acts through its AM1 receptor to reduce blood pressure. These findings demonstrate dysregulation of cerebellar AM system during hypertension, and suggest that cerebellar AM plays an important role in the regulation of BP. Likewise, they constitute a novel mechanism of BP control which has not been described so far.
Adrenomedullin (AM) is a 52-(human) or 50-amino acid (rat) peptide which shows some homology with calcitonin gene-related peptide (CGRP ) [1] and has therefore been included to the amylin, CGRP and calcitonin super-family [2, 3] . AM has two specific receptors, the AM1 and AM2 receptors, formed from the obligate co-expression of a class-B, G protein coupled receptor (GPCR), the calcitonin receptor-like receptor (CRLR) and receptor activity-modifying proteins (RAMP) 2 or 3, respectively [4] . The calcitonin gene-related peptide 1 (CGRP1) receptor is formed of a complex between CRLR and RAMP1 [4, 5] . AM1 receptors are highly selective for AM over CGRP and other
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peptides while AM2 receptors binds both AM and AM2 (intermedin) with high affinities [6] . AM also has appreciable affinity for the CGRP1 receptor [7] . AM is found in the peripheral circulation, in the cerebrospinal fluid and in several organs including the central nervous system (CNS) [1, 2, 8, 9, 10, 11] . In the CNS, AM and its receptors are particularly localized to the autonomic nuclei, including nucleus tractus solitarii (NTS), lateral parabrachial nucleus (LPBN) and rostral ventrolateral medulla (RVLM) and in cerebral cortex, pituitary gland, thalamus, hypothalamus, brainstem, amygdala and cerebellum [12, 13, 14, 15, 16, 17] . Also it was reported the presence of AM and its receptor components in cerebrospinal fluid-contacting nucleus [18] . In cerebellum, AM immunoreactivity is located in cerebellar Purkinje cells and mossy terminal nerve fibers as well as neurons of the cerebellar nuclei [13] . AM exerts several effects in the CNS. Central AM administration results in various neuroendocrine responses such as the inhibition of arginine vasopressin secretion induced by hypovolemic and osmotic stimuli, and the secretion of oxytocin by activating hypothalamic oxytocin-producing cells [19, 20] . In addition, central administration of AM increases urinary excretion of water, sodium and potassium, in a dose dependent manner in conscious hydrated rats [21, 22] , and microinjection of AM into the area postrema (AP) and the RVLM causes a hypertensive effect; while in the paraventricular nucleus (PVN) of the hypothalamus produces hypotension [23, 24, 25] . This evidence indicates that central AM may play an important role in body fluid homeostasis and central regulation of the cardiovascular system. AM immunoreactivity, AM binding sites and CRLR, RAMP1, RAMP2 and RAMP3 are expressed in rat cerebellum [13, 26, 27, 28] , however little is known about their functional role in this structure.
There is functional evidence suggesting that cerebellum may play a role in the regulation of arterial blood pressure (BP). In effect, it has been shown that stimulation of several regions of the cerebellum produces changes in arterial BP and heart rate [29, 30, 31] . Electric stimulus of cerebellar cortex posterior to vermis IX lobe, in anaesthetized rabbits induces bradycardia, BP fall and transient inhibition of sympathetic renal activity [32, 33] . On the contrary, electric stimulation of the rostral region of fastigial nucleus in anaesthetized rabbits produces a pressor response [34] . Several experimental and epidemiological studies have shown that AM and their receptors components expression are altered during hypertension [5] . In effect, it has been shown an increased expression of AM and its receptor components in rat aorta and ventricle during hypertension, possibly due to a compensatory response to the cardiovascular pathophysiological process [7, 35, 36] .
With this evidence, we were prompted to assess the possible relationship between cerebellar AM and the regulation of cardiovascular function. To do so, in our pioneer work we evaluated the distribution and levels of AM receptor binding sites in the brain of 16 week old normotensive Wistar Kyoto (WKY) rats and spontaneously hypertensive (SHR) rats, using 125 I-hAM13-52 as radioligand. As previously reported by Juaneda et al. [37] , we demonstrated that AM receptor sites are discretely and differentially distributed in the rat cerebellum cortex. However, higher levels of AM binding sites were detected in the granular cell layer of the cerebellum of SHR when compared with WKY rats, suggesting that AM binding sites density are altered in cerebellum during hypertension [38] . The increase in cerebellar AM receptors during hypertension could be interpreted as an up-regulation mechanism of cerebellar binding sites to compensate the increase in BP in SHR rats; or they could represent a primary alteration which would result in a secondary alteration in the autonomic regulatory mechanisms in cerebellum with the consequent increase in BP. The fact that AM binding sites are increased in SHR rat cerebellum when compared with WKY control suggest a possible role for cerebellar AM in the BP regulation.
To further get insight in this matter, we assess the expression of AM and its receptor components in the cerebellar vermis in WKY and SHR of 8 and 16 week old. We demonstrate the presence of AM and its receptor components in a specific cerebellar area such as the vermis of WKY and SHR rats [39, 40] , indicating the presence of CGRP1, AM1 and AM2 receptors in this area [3, 13, 37, 41] . In support to our findings it has been demonstrated by light and electron microscopy AM-like immunoreactivity in cerebellar Purkinje cells and mossy terminal nerve fibers as well as neurons of the cerebellar nuclei [13] . In addition, it has been shown the presence of RAMP1 and RAMP2 mRNA in Purkinje cells and RAMP3 mRNA in cerebellar granular cells [42] . Likewise, CRLR and RAMP1 were detected on the surface of the Purkinje cell bodies and in their processes [41, 43] . This evidence suggests a functional role for cerebellar AM and indicates that this peptide could participate in cerebellar functions as an autocrine/paracrine factor.
The expression and function of adrenomedullinergic system components could be altered in pathological conditions and during growth. Our results point to this possibility since they demonstrate that RAMP1, RAMP3 and CRLR expression in rat cerebellar vermis increases with age, without changes for AM and RAMP2 [40] . Similar findings have been shown for CGRP1 receptor (CRLR/RAMP1) expressed in cerebellar cortical neuron and glial, which suffer of marked changes during cerebellum development. Indeed, autoradiographic and immunofluorescence studies followed by con-focal analysis in rat cerebellum demonstrated a lower CGRP1 receptor density in Purkinje cell and molecular cells during development and their increase during maturity, suggesting that CGRP1 and its receptor may promote a coordinated development of cerebellar glial cells, an effect driven mainly by the CGRP released by climbing fibers [44] . Similar results has been described in the periphery, indeed Hwang et al. [45] found that in rats of 3, 12 and 20 months old, there were age-related increases in lung AM gene expression and peptide levels, as well as the mRNA levels of CRLR and RAMPs. Likewise, Wong et al. [46] demonstrated that in rats of 1, 7 and 21 days old, pre-pro-AM mRNA levels, CRLR and RAMP2 gene expression increased with age in lung, kidney, and heart but pre-pro-AM mRNA decreased with age in the adrenal gland. Meanwhile, AM levels increased with age in the lung but decreased with age in the kidney, the adrenal, and the heart. Furthermore, as shown in animal models, in midgestation human fetal lung, AM and its gene and protein expression as well as the AM1 receptor components CRLR and RAMP2 gene expression increased with increasing gestational age. Conversely, the expression of RAMP3, decreased with increasing gestational age [47] . The evidence and our results suggest that AM and its receptor components expression, in different tissues, follow different patterns of changes during development [39] .
To establish the pattern of CRLR, RAMP1 and RAMP3 expression during hypertension, we assessed cerebellar vermis CRLR, RAMP1 and RAMP3 expression in 16 week old WKY and SHR rats [40] . Our results support the notion of a dysregulation of AM cerebellar system during hypertension, since they demonstrate an up-regulation of Figure 1 . Effect of hypertension on adrenomedullin and its receptor components in cerebellar vermis. AM expression and of its receptor components CRLR, RAMP1, RAMP2 and RAMP3 are altered in SHR rats when compared with WKY rats (normal). In SHR rats AM y RAMP2 expression are reduced while CRLR, RAMP1 and RAMP3 expression are increased. "Modified and reprinted with permission" [39] cerebellar CGRP1 (CRLR+RAMP1) and AM2 (CRLR+RAMP3) receptors and a down-regulation of AM1 (CRLR+RAMP2) receptor during hypertension (Figure 1) . Effectively, in cerebellar vermis CRLR, RAMP1 and RAMP3 expression was increased significantly while RAMP2 was reduced in SHR rats compared with WKY. The reduction in AM expression in vermis of SHR rats could be responsible for the up-regulation of AM2 receptors and binding sites observed by autoradiography [38, 40] .
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It is known that CRLR/RAMP2 complex constitutes the pathway for AM biological activity, and it is believed that altered expression of RAMPs is associated with alterations of AM response [7] . In effect, during hypertension cerebellar cell phenotype changes from a high response (high expression of RAMP2) to a low response to AM (high expression of RAMP3) [7, 39, 40] , changes which may contribute to the development of hypertension. In effect, during hypertension there are dynamic changes in the expression of genes involved in AM signaling, particularly involving a switch from RAMP2 to RAMP3 expression, which may underlie the marked decrease in AM expression in cerebellum and/or represent an altered responsiveness [7, 39, 40] . Furthermore, upregulation of RAMP1/RAMP3 expression would promote the interaction of AM with CGRP1 and AM2 receptors, rather than AM1 receptors, thereby favoring the compensatory mechanism to increased BP. Alternatively, these changes could be the initial disturbance that would result in dysregulation of the mechanisms controlling BP, since these changes are present from the early stages of life (8 week) of hypertensive rats.
Several studies support that hypertension may influence AM and its receptor components expression. In fact, AM and its receptor components expression are altered in cardiovascular system and in CNS during hypertension. It has been demonstrated increases in cardiovascular AM generation and an up-regulation of the gene expression of ventricles and aortas AM and its receptor components CRLR, RAMP1 and RAMP3, during L-NAME induced hypertension [36] . Similarly, expression of AM, RAMP2 and RAMP3, but not CRLR and RAMP1 mRNAs was increased in left ventricular cardiomiocytes of hypertensive rats [48] . Changes of CNS adrenomedullinergic system during hypertension have been also shown in brain areas. It was demonstrated that chronic hypertension induced by one-kidney-one-clip method, did not alter brain RAMP1 expression while significantly reduced RAMP2 and CRLR, suggesting a stoichiometric shift between CGRP and AM receptors in favor to the CGRP receptor [11] . Furthermore, hypertension induced by restraint stress reduced pre-pro-AM mRNA level in the hypothalamic PVN and supraoptic nucleus (SON), NTS, dorsal motor nucleus of the vagus, AP, and subfornical organ [49] . Likewise, increased BP induced by phenylephrine administration elicited a decrease in RAMP2 mRNA expression in the PVN and NTS [50] , suggesting that changes in RAMP2 mRNA expression may influence brain AM to regulate sympathetic activity. Effectively, it has been shown that chronic stress induced by immobilization for 7 consecutive days produced an enhanced expression of AM in the cerebrospinal fluid-contacting nucleus [18] and chronic foot-shock and noise stress for 15 consecutive days produced an up-regulation of preproAM mRNA, in the hypothalamus-pituitary-adrenal (HPA) axis, and down-regulation in the medulla oblongata and midbrain. This was associated with an increased RAMP3 mRNA expression in the hypothalamus and pituitary gland and a decrease in the adrenal gland and midbrain [51] . In this regard, Li et al. [51] suggested that increased hypothalamic pre-pro-AM, RAMP2 and RAMP3 may constitute a protection mechanism for resetting hypertension induced by chronic stress, through a direct or indirect mechanism of action on cardiovascular function. Meanwhile, the decrease in the expression of pre-pro-AM in medulla, where AM administration causes an increase in BP by increasing the sympathetic outflow, could provide a protective mechanism of AM to reset BP. Taken together the evidence suggests that AM may be related to the development of the stress-induced hypertension.
AM activates several signaling pathways and regulates reactive oxygen species metabolism, both peripherally and centrally [52, 53, 54] . Little is known about the signaling pathways associated to AM receptor in cerebellum. Therefore we proceeded to assess the signaling pathways mediating AM action in rat cerebellum vermis, as well the receptor involved, by the stimulation of the tissue in vitro with AM, in the presence or absence of specific blockers of AM receptor subtypes: AM or CGRP . Our findings demonstrate that in cerebellum, AM activates extracellular signal-regulated kinases (ERK), increases cyclic adenosine monophosphate (cAMP) production probably through the activation of protein kinase A (PKA); increases cyclic guanosine monophosphate (cGMP) production and nitric oxide (NO) accumulation. These effects are mediated through the activation of AM 1 receptor, since AM blunted AM action, meanwhile AM increase of cAMP production is also mediated through stimulation of AM2 and CGRP receptors [55, 56] . In this sense, Endo et al. [57] found that NO-cGMP-protein kinase G (PKG) pathways plays an important role in the activation of ERK1/2 in Purkinje cells of rat cerebellum. Moreover, it is reported that the NO/cGMP pathway could act as a neurotransmitter in the cerebellum [58] since it was found high levels of the enzyme guanylyl cyclase (GC) [59] and cGMP [60] in Purkinje cells. Furthermore, immunohistochemical studies revealed high expression of cGMP-dependent protein kinase in cerebellar Purkinje cells [61] . Additionally, nitric oxide synthase (NOS) and soluble GC are colocalized and activated in various regions of the cerebellum [62] . In contrast to cAMP, which is homogeneously distributed in different brain areas, cGMP is 10 to 50 times more concentrated in the cerebellum than in other brain areas. cGMP is believed to exert its effects through cGMP-dependent protein kinases (cGPK), the activity and expression is specifically detected in the cerebellum, mainly concentrated in the Purkinje cells [61] .
Moreover, AM is a peptide with pleiotropic effects including cell growth, migration, apoptosis, inflammation, angiogenesis and secretion of hormones. It has been shown in heterozygous mice for AM, perivascular inflammation in coronary arteries and an increase of the systemic and local oxidative stress, which is reversed with supplementation of AM, indicating that AM plays a protective role against oxidative stress acting as an endogenous antioxidant in vivo. Indeed, AM has been described as an endogenous antioxidant substance as it is cytoprotective against organ damage [63, 64] . Thus, we were interested to establish the role of AM in the regulation of cerebellar metabolism of reactive oxygen species by assessing the effect of AM on thiobarbituric acid reactive substances (TBARS) production and the activity of three antioxidant enzymes: catalase (CAT), glutathione peroxidase (GPx) and superoxide dismutase (SOD), in the vermis of the cerebellum of male Sprague Dawley rats. In addition, we assessed the role AM receptor subtypes and PKA activity. Our findings demonstrate that in cerebellum, AM decreased TBARS production and CAT, GPx and SOD basal activity (Figure 2) , as reported by other researchers in other organs such as kidney and liver [65, 66] . The decrease in enzyme activity suggests that AM is capable of reducing reactive oxygen substances (ROS) production, because the decreased of antioxidant enzymes activity was accompanied by a decrease in the production of lipid peroxidation. In fact, it has been reported that AM has antioxidant properties as AM reduces the overproduction of ROS [67, 68] and these effects can protect various organs damage induced by several stressors [69] , suggesting that AM has protective action against the vascular response to injury, possibly through inhibition of the production of oxidative stress [70] . Several are the pathways that might mediate the inhibitory action of AM on the basal activity of antioxidant enzymes in rat cerebellar vermis. Our [55] results point to the involvement of PKA, since pretreatment with PKI-(6-22) amide, a PKA inhibitor, was able to reverse the inhibitory effect of AM on the basal activity of antioxidant enzymes, as has been reported by other studies in other tissues [63, 71] . AM and CGRP blunted AM-induced decrease of antioxidant enzymes activity indicating that this effect is mediated through stimulation of both, AM and CGRP 1 , receptors. Our results support the role of AM in the regulation of cerebellar antioxidant enzyme activity and suggest a physiological role for AM in cerebellum [72] . In summary, in cerebellum AM exerts its effects through several signaling pathways such NO/cGMP, AC/cAMP and/or ERK, suggesting the presence of a functional adrenomedullinergic system in cerebellum [55, 72] (Figure 2 ).
We hypothesize that if there is an alteration of AM receptors expression and binding sites in cerebellum during hypertension [39, 40] , we could also expect dysregulation of signaling pathways in the cerebellar vermis during high blood pressure. Our results point to this possibility since they demonstrated in adult male WKY that AM reduced antioxidant enzymes activity and TBARS production, while in SHR rats AM was unable to affect this signaling pathways [73] , indicating that during hypertension there seems to exist a dysregulation of basal antioxidant capacity of AM. Alternatively, the absence of response to the AM on the basal activity of antioxidant enzymes in the cerebellar vermis of SHR rats could be due to change in the expression pattern of AM receptor components observed in the cerebellar vermis during hypertension [39, 40, 73] .
In addition, cerebellum ERK signaling pathway is altered during hypertension since it was observed an increase in basal ERK1/2 activation in the cerebellar vermis of SHR rats which was higher in magnitude of that obtained in WKY rats; and in cerebellum of both SHR and WKY rats AM activated ERK1/2, however this effect was smaller in magnitude in hypertensive rats [74] , suggesting a role of this signaling pathway in the cerebellar mediated control of BP, similarly to those reported by other in other organs [75, 76, 77] .
In regard to AM signaling through cGMP/NO production in cerebellum vermis during hypertension, we demonstrated that in cerebellar vermis AM-induced cGMP/NO production is impaired, since in WKY rats AM increased cGMP/NO production, while in SHR rats AM was unable to stimulate this signaling pathway; thus confirming the hypothesis of dysregulation of cerebellar adrenomedullinergic signaling during hypertension [56] . The intimate mechanism by which NO and its dysregulation in the cerebellum is involved in the control of BP has not yet been established, nor our results allow us to infer. However, in other areas of the CNS it appears to be related to the regulation of sympathetic outflow. Indeed, non-specific NOS inhibition through systemic administration of analogues of L-arginine, causes a vasoconstrictor response and increased BP in both humans and animals [78] , this due to the removal of tonic vasodilation coupled with activation of the sympathetic nervous system. Indeed, the level of central sympathetic tone in L-NAME-treated rats is much greater than in non-treated rats indicating that neuronal NO exerts an inhibitory tonic effect on sympathetic nerve activity, since during NOS inhibition with L-NAME, administration of ganglionic blockers or beta-adrenergic blockers caused a significantly greater decrease in mean arterial pressure (MAP) compared to control rats MAP [79] .
Taken together, our results indicated an alteration of AM-induced TBARS and cGMP/NO production, antioxidant enzymes reduction and ERK1/2 activation during hypertension. The absence of response to the AM on the basal activity of antioxidant enzymes in the cerebellar vermis of SHR rats could be due to change in the expression pattern of AM receptor components observed in the cerebellar vermis during hypertension, because as we have previously shown, during hypertension there are an increased expression CGRP1 receptor (CRLR + RAMP1) and AM2 (RAMP3 + CRLR), and decreased expression of AM1 receptor (RAMP2 + CRLR), suggesting that the optimal expression of AM2 receptor is necessary for proper signaling AM [40] .
If cerebellar adrenomedullinergic system exerts a physiological role, it is plausible to expect that the AM administered into the cerebellum may cause actions in cardiovascular regulation. Our findings point to this possibility since they demonstrate, for the first time, that microinjection of AM into the cerebellar vermis of hypertensive rats causes a powerful and significant hypotensive response, which is specific and dose-dependent. This hypotensive effect is manifested only during hypertension since AM microinjection into the cerebellar vermis was not able to reduce BP in normotensive rats. The specificity of the hypotensive action of AM administered into the cerebellar vermis is based on the fact that microinjection of the peptide outside the vermis did not cause the hypotensive effects in SHR, and in situ administration of a pressor peptide such as angiotensin II (ANG II) into cerebellar vermis did not altered BP [80] . To establish the receptor subtype involved in AM action in vivo, animals received microinjections of AM , an AM1 receptor antagonist, or the CGRP1 receptor antagonist, CGRP into the cerebellar vermis, administered simultaneously with AM or vehicle microinjection. Our data show that AM's actions in the cerebellar vermis in SHR rats are mediated by AM1 receptor, as AM , an AM1 receptor specific antagonist, blunted AM's hypotensive effect when both agents were injected together. These results provide the first functional evidence in vivo of a role for AM in the cerebellar vermis in the control of BP.
The possible cause of the difference in the AM action among normotensive and hypertensive rats may be variable and has been described for other brain structures, since the infusion of AM reduces BP in both normotensive and hypertensive rats in a dose dependent manner; however the fall in BP was higher in hypertensive rats compared to the normotensive [81] . Similarly, it was reported that RVLM neurons of SHR rats are more sensitive and have an increased response to ANG II with respect to the WKY [82] . Therefore, the hypotensive effect induced by the intracerebellar administration of AM in SHR could be due to an increase in sensitivity and response in SHR compared with WKY rats. Alternatively, this differential response may be the manifestation of the cerebellar dysregulation of signaling pathways, or AM and AM1 receptor expression which are reduced during hypertension [39, 40, 79] .
In conclusion, our study demonstrated a dysregulation of cerebellar vermis AM, its receptor components and AM signaling pathways during hypertension. In addition, they show that under hypertensive conditions AM administered into cerebellar vermis exerts a profound, dose-dependent hypotensive effect. These actions are mediated through AM1 receptor since there were blocked by AM 22-52, but not by CGRP . These data suggest the existence of a cerebellar adrenomedullinergic system of physiological relevance in BP regulation. Likewise, they constitute a novel mechanism of BP control which has not been described so far.
